ArticleVeterinary dermatology2026
Fluorescent Light Energy (FLE) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma (CTCL).
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fluorescent Light Energy (FLE) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma (CTCL).Veterinary dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFluorescent light energy (FLE; Phovia, Vetoquinol) is a photobiomodulation therapy that promotes healing and reduces inflammation. Cutaneous epitheliotropic lymphoma (CTCL) is a neoplastic skin disease with limited treatment options. Although FLE is not considered genotoxic, its use in neoplastic conditions is off-label. HYPOTHESIS: To assess the safety and clinical effect of FLE as an adjunctive treatment for canine CTCL. ANIMALS: Eight client-owned dogs were diagnosed with CTCL via biopsy analysis and immunohistochemical analysis. MATERIALS AND
methodsEach dog had one CTCL lesion treated with FLE with a lesion serving as a vehicle-control. Treatments were administered weekly for 6 weeks, followed by 3 months follow-up. Focal nodular lesions were assessed weekly using Response Evaluation Criteria of Solid Tumours (RECIST), while diffuse lesions were evaluated using the Canine Epitheliotropic Lymphoma Extent and Severity Index (CELESI). Owner-perceived efficacy and quality of life were assessed using the Owner Global Assessment of Treatment Efficacy (OGATE) and a quality-of-life (QoL) survey.
resultsNo statistically significant differences in estimated marginal means were observed between sites at any time point (p > 0.05). Within-subject analyses suggested more favourable lesion progression at FLE-treated sites, and 75% of RECIST-evaluated FLE lesions maintained stable disease. Diffuse FLE-treated lesions demonstrated clinical severity reductions of ≤ 35.3%. Over 66% of owners rated treatment response as 'fair' to 'excellent' on the OGATE. One dog was withdrawn at Week 3 as a consequence of unrelated worsening. CONCLUSIONS AND CLINICAL RELEVANCE: FLE appears to be a safe adjunctive therapy for canine CTCL, although statistically significant treatment effects were not demonstrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.